Johnson & Johnson, US4781601046

Johnson & Johnson stock at USD 271.22 on September 25, 2026

Published on 09/28/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock last traded at USD 271.22 on September 25, 2026. The company reported positive topline results from a Phase 4 TREMFYA study.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground
Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson stock last traded at USD 271.22 on the NYSE on September 25, 2026, at 20:00 UTC. The shares were up 0.20 percent from the prior close, according to the latest session data.

Reference session

Johnson & Johnson is scheduled to be the subject of the next regular-session trading activity on the NYSE. The September 25 session remains the latest dated trading reference for JNJ in the available market data.

Company reports TREMFYA study results

In a September 25, 2026 release, Johnson & Johnson said TREMFYA met the primary and major secondary endpoints in the Phase 4 STAR study of biologic-naive adults with active psoriatic arthritis and axial involvement.

The company said the primary endpoint assessed improvement at Week 24 versus placebo using the Bath Ankylosing Spondylitis Disease Activity Index. Major secondary endpoints included reductions in axial symptoms and MRI-confirmed inflammation of the sacroiliac joints, according to the release. The STAR study enrolled 411 participants and included a 24-week placebo-controlled treatment period followed by a 24-week active-treatment period.

Disclaimer...

en | US4781601046 | JOHNSON & JOHNSON | boerse | 70191148 | bgmi